Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.46) by 15.22 percent.

Recursion shares tumbled 11% in premarket.

This is a 26.19 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $4.55 million which missed the analyst consensus estimate of $19.04 million by 76.13 percent. This is a 58.26 percent decrease over sales of $10.89 million the same period last year.